Memorial Sloan Kettering Cancer Center (MSK) today announced that its state-of-the-art cancer care pavilion currently under construction will be named The Kenneth C. Griffin Pavilion at Memorial Sloan Kettering Cancer Center.
emorial Sloan Kettering Cancer Center (MSK) is proud to announce a new community mural, “One Hundred Views,” by artist Naomi Reis. The inaugural MSK mural was created in collaboration with fifth-grade students from P.S. 183 Robert L. Stevenson Elementary School, the neighboring school on East 66th Street.
Cycle for Survival Surpasses $400 Million Raised for Rare Cancer Research
Vinod Balachandran, MD, surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at Memorial Sloan Kettering Cancer Center, has been named to the inaugural edition of the Post Next 50, a list of up-and-coming changemakers shaping society in 2025.
MSK researchers are helping to map the landscape of viruses that infect us all, and to analyze the impact they have on human health and disease.
New research from Memorial Sloan Kettering Cancer Center (MSK) provides a clearer understanding of glioblastoma heterogeneity to aid development of new therapies; sheds light on mechanisms of cellular plasticity; presents a new imaging technique that could improve the diagnosis of brain diseases by revealing how different parts of the brain are metabolizing nutrients; describes a new method to aid the study of rare but influential cell populations; and identifies a potential treatment for malignant peripheral nerve sheath tumors.
Kimberly Feigin, MD, has been named Chief of the Breast Imaging Service within the Department of Radiology.
Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate disparities in cancer outcomes.
Researchers MSK and their collaborators at Mount Sinai have developed an artificial intelligence-based model to predict who will benefit from immune checkpoint inhibitors using only routine blood tests and clinical data.
New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.
New research from Memorial Sloan Kettering Cancer Center (MSK) uncovers clues about how cells control a key DNA repair protein; develops a new method for studying gene amplifications in cancer; sheds new light on tumor suppressor genes; shows MSK-IMPACT® could be used for HLA genotype screening to predict response to cellular therapies; identifies a possible strategy to overcome immune evasion in ovarian cancer; and finds strong support for telemedicine visits among cancer patients.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) continued to make strides against cancer in 2024. Laboratory research teams across the institution worked to advance the global understanding of cancer and to develop new therapies, while also making fundamental insights into human biology and disease.
New research presented during the 2024 San Antonio Breast Cancer Symposium (SABCS) reveals a new machine learning model that could change the way metastatic breast cancer is treated in the future. By combining clinical and genomic data, physician-scientists from Memorial Sloan Kettering Cancer Center (MSK) developed a tool that could help improve predictions of how people with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer respond to CDK4/6 inhibitors, a class of oral medications that control cell division and are often prescribed in combination with hormone therapy to treat this subset of patients.
A new laboratory study provides evidence about how advanced age can be protective against cancer — with implications for treating patients in different age groups.
NEW YORK, December 4, 2024 – Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:
New research from Memorial Sloan Kettering Cancer Center (MSK)& investigates how pancreatic cancer cells regulate their genome to avoid immune attack; shows promise against glioblastoma in mouse models; and develops a new method to study cancer evolution.
New MSK research marks a potential advance against RAS-driven cancers; breaks down data silos to better predict cancer outcomes with the help of artificial intelligence (AI); identifies two enzymes vital for maintaining brain health; uncovers how changes to “helper” proteins drive cancer cell survival; develops a new model for investigating lung cancer metastasis; and uses AI to improve outcome predictions in sarcoma.
Along with defending against pathogens, the body’s innate immune system helps to protect the stability of our genomes in unexpected ways — ways that have important implications for the development of cancer, researchers at MSK are discovering.
Ivan Maillard, MD, PhD, has been named Head of the Division of Hematologic Malignancies within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).
Dr. Deb Schrag, Chair of the Department of Medicine, and Dr. Lorenz Studer, Director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center (MSK), have been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists worldwide.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right